OakChart

Lycia Therapeutics Inc

LYCAHealthcare·Biotechnology·USA·Small·NASD·Nov 12 • 1:57 PM ET

32.54+1.10 (3.51%)
2026-11-12 19:58 CET
Market cap
$1.88B
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
-
Compare

Price

LYCA against its price
Terms
Patternshover a marker to name it
25.0030.0035.001.1M2.3MVolumeOct 26Nov 26LYCAclose 32.5432.5452w high52w low

10.8% under the 52-week high of 36.49 on 23 Oct 2026. 52-week low 22.19 on 23 Oct 2026. Last 15 sessions, 64.5% high to low. This session is unfinished.

Volume 0.96× normal · the line is the 50-bar volume average

Setup
CANSLIM 1 of 6 — fails: 52-Week High/Low: 0-10% below High; Institutional Ownership: Over 50% — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); Performance: Year +50%
VCP 2 of 6 — fails: 52-Week High/Low: 0-10% below High; Average True Range: Under 2 — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200
Minervini 0 of 4 — fails: 52-Week High/Low: 0-10% below High — not on the tape: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; Performance: Year +50%
Zanger 2 of 5 — fails: 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5 — not on the tape: 200-Day Simple Moving Average: Price above SMA200
Leaders 0 of 5 — fails: Average Volume: Over 500K; 52-Week High/Low: 0-10% below High — not on the tape: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2 — not on the tape: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — not on the tape: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 0 of 5 — not on the tape: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1); P/E: Under 25; Current Ratio: Over 1
Value 0 of 4 — not on the tape: P/E: Under 15; P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1)
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 0 of 4 — fails: Average Volume: Over 500K — not on the tape: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 1 of 4 — fails: Institutional Ownership: Over 30% — not on the tape: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 0 of 3 — fails: Average Volume: Over 500K — not on the tape: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200

Profile

LYCA
52-week range, 72% of the way up
22.1936.49

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

IPOOct 23, 2026
ATR, 14d3.40
Rel volume0.96
Inst own12.34%

Snapshot

6 groups

Valuation

Index-
Market Cap$1.88B
Enterprise Value-
Income-
Sales-
Book / share-
Cash / share-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOOct 23, 2026

Ratios

Price / earnings-
Forward price / earnings-
Price / earnings / growth-
Price / sales-
Price / book-
Price / cash-
Price / free cash flow-
Value / cash profit-
Value / sales-
Quick Ratio-
Current Ratio-
Debt / equity-
Long-term debt / equity-
Options and shortNo / Yes

Earnings

Earnings / share-
Earnings next year-
Earnings next quarter-
Earnings this year-
Earnings next year-
Earnings growth, 5 years-
Past earnings growth- -
Past sales growth- -
Earnings vs last year-
Sales vs last year-
Earnings vs last quarter-
Sales vs last quarter-
Earnings-
Surprise- -

Ownership

Insiders own-
Insider trades-
Institutions own12.34%
Institution trades16.49%
Return on assets-
Return on equity-
Return on capital-
Gross Margin-
Operating margin-
Profit Margin-
20-day average12.79%
50-day average12.79%
200-day average12.79%

Technical

Shares out55.03M
Shares floating-
Short / float-
Short ratio0.65
Short interest0.30M
52-week high36.49 -10.8%
52-week low22.19 +46.7%
Volatility6.70% -
Average range3.40
Strength index58.14
Market sensitivity-
Relative volume0.96
Avg Volume469.26K
Volume315,889

Performance

Perf Week13.00%
Perf Month-
Perf Quarter-
Perf Half Y-
Perf YTD13.99%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recommendation-
Target Price-
Prev Close31.44
Price32.54
Change %3.51%

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Venrock Healthcare Capital Par10% OwnerNov 02 '26Buy26.958,305223,8206,858,542Nov 04 05:12 PM
Venrock Healthcare Capital Par10% OwnerOct 28 '26Buy25.4515,000381,7286,840,233Oct 30 07:25 PM
Venrock Healthcare Capital Par10% OwnerOct 30 '26Buy26.289,004236,6536,850,237Oct 30 07:25 PM
Venrock Healthcare Capital Par10% OwnerOct 29 '26Buy26.331,00026,3306,841,233Oct 30 07:25 PM
Venrock Healthcare Capital Par10% OwnerOct 26 '26Buy18.041,952,70535,222,7916,785,437Oct 27 06:38 PM
Venrock Healthcare Capital Par10% OwnerOct 23 '26Buy25.9152,9391,371,67652,939Oct 27 06:38 PM
Venrock Healthcare Capital Par10% OwnerOct 27 '26Buy26.6239,7961,059,3966,825,233Oct 27 06:38 PM

Held by

AUM
TickerCompanyAUM
TMEDT. Rowe Price Health Care ETFAUM: 39.86M
TDNAT. Rowe Price Biotech ETFAUM: 11.51M
TSEET. Rowe Price Small Cap ETFAUM: 10.86M

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual
Period
EPS, quarterly
Period
Sales, annual
Period
Sales, quarterly
Period
Shares, annual
Period
Shares, quarterly
Period

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.3M-747.92K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-044Statement of changes in beneficial ownership of securities2026-11-02SEC
2026-10-30SCHEDULE 13GSEC
2026-10-304Statement of changes in beneficial ownership of securities2026-10-28SEC
2026-10-284Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-23SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-264Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-10-23S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-10-23424B4SEC
2026-10-22EFFECTEffectiveness filing by commission orderSEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-22S-1MEFA new registration statement filed under Rule 462(b) to add securities to a prior related effective registration statement filed on Form S-1SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-22CERTSEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC
2026-10-223Initial statement of beneficial ownership of securities2026-10-22SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11223.82K100
2026-1038.30M600
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
-

Funds

Fund% owned
-

OakChart. LYCA. Cached 15 minutes. Terms

Some panels did not load: ratings, news.